Sorry, you need to enable JavaScript to visit this website.
跳转到主要内容


鲁比前列酮

鲁比前列酮
CAS Number: 136790-76-6

鲁比前列酮

治疗类别
防便秘
API技术
前列腺素
剂型
口服固体制剂
瑞迪博士研发状态
可得到
注册备案情况
USA
创新品牌(美国)
Amitiza

Mechanism of Action

Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A–independent fashion.

By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.

Lubiprostone, via activation of apical ClC-2 channels in intestinal epithelial cells, bypasses the antisecretory action of opiates that results from suppression of secretomotor neuron excitability.

Activation of ClC-2 by lubiprostone has also been shown to stimulate recovery of mucosal barrier function and reduce intestinal permeability via the restoration of tight junction protein complexes in ex vivo studies of ischemic porcine intestine.

Indication

Amitiza is a chloride channel activator indicated for the treatment of:

  • Chronic idiopathic constipation (CIC) in adults. 
  • Opioid-induced constipation (OIC) in adult patients with chronic, non-
  • Cancer pain, including patients ith chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. 
  • Limitations of Use: Effectiveness of Amitiza in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. 
  • Irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old.

Dr. Reddy的专长

Dr. Reddy总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Reddy博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Reddy博士 鲁比前列酮 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

如果您有任何特定于国家的要求,我们将为您提供帮助。

联系我们

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com |   +91 40 49002253

免责声明

受有效专利保护的产品不得在销售此类产品构成专利侵权的国家/地区销售。可获得性可能仅限于某些市场或国家/地区。有关可获得性和产品适用性的更多信息,请 我们联系 .

所有产品信息,包括有关活性药物成分(API)、适应症和可能的作用机制的信息均基于公开的产品标签。

  给我们发电子邮件: api@drreddys.com |   +91 40 49002253